Astellas 0113-CL-2001 CMV Vaccine

Investigator: Richard Knight, MD

Study Coordinator: Joy Nolte Fong

Status: Enrolling Number: NCT01974206

Phone: 713.441.6314

Protocol Number: Pro00010448


The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also evaluate the safety of ASP0113 in this patient population.
More to Explore